- Home
- FYBR vs CORT Comparison
FYBR vs CORT Comparison
Compare FYBR & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FYBR | CORT |
|---|---|---|
| Founded | 1935 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.2B | 7.6B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | FYBR | CORT |
|---|---|---|
| Price | $38.17 | $82.07 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 2 | 6 |
| Target Price | N/A | ★ $130.20 |
| AVG Volume (30 Days) | ★ 2.6M | 821.3K |
| Earning Date | 10-28-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.87 |
| Revenue | ★ $6,106,000,000.00 | $741,172,000.00 |
| Revenue This Year | $5.86 | $23.79 |
| Revenue Next Year | $3.66 | $40.97 |
| P/E Ratio | ★ N/A | $92.87 |
| Revenue Growth | 4.25 | ★ 17.92 |
| 52 Week Low | $34.60 | $49.00 |
| 52 Week High | $38.25 | $117.33 |
Technical Indicators
Market Signals| Indicator | FYBR | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 63.59 | 51.62 |
| Support Level | $37.88 | $78.07 |
| Resistance Level | $38.25 | $89.00 |
| Average True Range (ATR) | 0.09 | 3.40 |
| MACD | 0.01 | -0.11 |
| Stochastic Oscillator | 78.21 | 39.42 |
Price Performance
Historical ComparisonAbout FYBR Frontier Communications Parent Inc.
Frontier Communications Parent Inc is a communications and technology provider offering broadband services. The company provides voice services, including data-based voice over Internet protocol (VoIP) and unified communications as a service (UCaaS), as well as long-distance and voice messaging services, to consumer and business customers in all its markets.
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.